OR WAIT 15 SECS
This article contains online-exclusive supplemental material for Malik's article entitled, "Allogenic Versus Autologous Stem-Cell Therapy."
Leaders in the fields of stem-cell regulation, manufacturing, and commercialization were interviewed to establish the following:
Selected individuals were sent an email requesting an interview. A total of 186 emails were sent, resulting in 32 individuals ultimately being interviewed (10 face-to-face, 19 by phone, and 3 via email). Interviews did not follow a rigid question format. The following four groups were interviewed:
A cost range for each component of the manufacturing process was established on the basis of minimum and maximum estimates obtained (see Table I). The cost range applies to both allogeneic and autologous therapy unless otherwise stated.
Table I: Cost range for each component of the manufacturing process for stem cell therapy. 1Â£ = US $1.6.
The following categories of data were calculated for allogeneic and autologous therapy:
Table II: Cost to set up a manufacturing facility capable of producing 2500 doses of stem-cell therapy a year. 1Â£ = US $1.6.
Table III: Cost to manufacture 2,500 units of stem cell therapy a year, 1Â£ = US $1.6.
Table IV: Cost to manufacture 2500 units of stem cell therapy a year factoring in the cost of setting up the manufacturing facility, 1Â£ = US $1.6.
1. Y. Li and M. Chopp, Neurosci. Lett. 456, 120–123 (2009).
2. O.Y. Bang et al. Ann. Neurol. 57, 874–882 (2005).
3. L. Jackson et al., J. Postgrad. Med. 53, 121–127 (2007).
4. G. Chamberlain, et al., Stem Cells 25, 2739–2749 (2007).
Related Content:Upstream Processing